Compare Gilead Sciences, Inc. (GILD) vs Procter & Gamble Co (PG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs Procter & Gamble Co — how do they compare? Gilead Sciences, Inc. trades at $133.1 (market cap $163.51B), while Procter & Gamble Co trades at $150.34 (market cap $344.75B). The key difference: Procter & Gamble Co is far larger — about 2.1× Gilead Sciences, Inc.'s market cap, and Procter & Gamble Co pays the higher dividend (2.94%). Which is the better fit depends on your goals.
| GILD | PG | |
|---|---|---|
Market Cap | $163.51B | $344.75B |
Sector | Health | Consumer Staples |
52-Week High | $155.80 | $167.18 |
52-Week Low | $108.22 | $138.10 |
Enterprise Value | $178.05B | $370.23B |
Dividend Yield | 2.49% | 2.94% |
Volume | — | 6,423,436 |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $130.04, down 1.04% on the day, with technical indicators showing a bearish bias while fundamentals remain strong. The company has beaten earnings expectations for three consecutive quarters, maintains robust profitability with a 30.99% net income margin, and recently secured FDA and European Commission approvals for expanded use of its oncology drug Trodelvy. Analyst consensus remains overwhelmingly positive with a $152.83 price target representing 17.5% upside potential.
The outlook for GILD is favorable with strong earnings momentum, expanding oncology portfolio, and solid cash generation, though risks include patent expirations, competitive pressures in HIV treatments, and recent negative cash flow trends. The stock presents a compelling opportunity for investors seeking exposure to a profitable biopharmaceutical company with growth catalysts, supported by Wall Street's bullish sentiment and recent regulatory wins.
Procter & Gamble (PG) trades at $146.12, down 1.52% with bearish technical signals but strong fundamentals. The company maintains consistent revenue growth, with 2025 revenue reaching $84.28B and net income of $15.97B. Recent earnings have consistently beaten expectations, and analyst consensus remains positive with a $161.71 price target. Dividend payments continue with $1.09 per share payouts, supporting income-focused investors amid market volatility.
PG offers stability with 69 consecutive years of dividend growth and efficient cash flow generation, though premium valuation multiples and modest growth outlook present near-term headwinds. The stock's technical weakness contrasts with fundamental strength, creating potential for recovery if earnings momentum continues. Key risks include consumer demand softness and competitive pressures in the consumer staples sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About Procter & Gamble Co
The Procter & Gamble Company manufactures and markets consumer products in countries throughout the world. The Company provides products in the laundry and cleaning, paper, beauty care, food and beverage, and health care segments. Procter & Gamble products are sold primarily through mass merchandisers, grocery stores, membership club stores, drug stores, and neighborhood stores.
Read more on PG →
